Related to GSK Reports Japanese Clearance for ITP Drug as Partner Ligand Gets $2M in Govt Grants

• Astex Transfers Anticancer Epigenetics Collaboration to Partner GSK
  
• Japan's Approval of Regnite for RLS Triggers $10M Payment from Astellas to XenoPort
  
• Retrophin Takes on Ligand’s Nephropathy Candidate DARA for $1M Up Front
  
• GSK, Angiochem to Work on CNS-Penetrating Drugs for Lysosomal Storage Diseases
  
• Agenus Expands QS-21 Adjuvant License with GSK for $9M
  
• Wellcome Trust Awards University of Dundee, GSK £8.6M for Tropical Disease Therapies
  
• GSK Taps Epistem for Amplification Platform to Identify Fibrosis Biomarkers
  
• GSK, Theravance Report Mixed Bag of Data for Relovair in COPD, Asthma
  
• GSK’s Votrient Approved in U.S. for Treating Soft Tissue Sarcoma
  
• GSK, Canadian Center Launch Funds to Bolster Commercialization of Research
  
• GSK Pays Basilea £146M Up Front for Approved Dermatology Product Toctino
  
• FDA Approves GSK’s MenHibrix Meningitis Vaccine
  
• FDA Approves Novartis' Flucelvax
  
• GSK Parts Ways with Impax
  
• Chinese Regulator Grants Label Extension for 3SBio’s TPIAO as Treatment for ITP
  
• FDA Green-Lights HGS and GSK’s Systemic Lupus Erythematosus Drug Benlysta
  
• FDA Clears Valeant and GSK’s Potiga for Partial-Onset Seizures in Adults
  
• EC Clears HGS and GSK’s Systemic Lupus Erythematosus Antibody Therapy Benlysta
  
• FDA Approves XenoPort, GSK’s Horizant for Managing Postherpetic Neuralgia
  
• GSK Wins EC Clearance for Drug to Treat Idiopathic Thrombocytopenic Purpura